Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes

Open access
Poulos, Rebecca C., Olivier, Jake, Wong, Jason W.H. · 2017 · Nucleic Acids Research

Published version of a preprint

Abstract

Methylated cytosines (5mCs) are frequently mutated in the genome. However, no studies have yet comprehensively analysed mutation-methylation associations across cancer types. Here we analyse 916 cancer genomes, together with tissue type-specific methylation and replication timing data. We describe a strong mutation-methylation association across colorectal cancer subtypes, most interestingly in samples with microsatellite instability (MSI) or Polymerase epsilon (POLE) exonuclease domain mutations. By analysing genomic regions with differential mismatch repair (MMR) efficiency, we suggest a possible role for MMR in the correction of 5mC deamination events, potentially accounting for the high rate of 5mC mutation accumulation in MSI tumours. Additionally, we propose that mutant POLE asserts a mutator phenotype specifically at 5mCs, and we find coding mutation hotspots in POLE-mutant cancers at highly-methylated CpGs in the tumour-suppressor genes APC and TP53. Finally, using multivariable regression models, we demonstrate that different cancers exhibit distinct mutation-methylation associations, with DNA repair influencing such associations in certain cancer genomes. Taken together, we find differential associations with methylation that are vital for accurately predicting expected mutation loads across cancer types. Our findings reveal links between methylation and common mutation and repair processes, with these mechanisms defining a key part of the mutational landscape of cancer genomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkx463

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Association between mutation accumulation and methylation in colorectal cancer subtypes. (A) Colorectal cancer (n = 61) mutation profile and average methylation profile from normal colon whole genome bisulfite sequencing (WGBS) data, around transcription start sites (TSSs). Nucleotide-resolution mutation data (light beige), together with mutation data in 25 bp bins (dark beige) is shown. (B) Correlation between mutations per megabase (Mb) at CpG dinucleotides and fractions of CpGs methylated (using normal sigmoid colon tissue WGBS methylation data) across autosomes in Polymerase epsilon exonuclease domain mutation (POLE-mutant) colorectal cancers, those with microsatellite instability (MSI) or those that are microsatellite stable (MSS). Genome-wide data is binned for each colorectal cancer subtype (bins of 0.1 methylation), along with r2 and significance from Pearson's regression. The comparison of MSI and POLE-mutant slopes with MSS slopes was calculated by linear regression on binned data, with MSS as the reference factor.
Figure 1. Association between mutation accumulation and methylation in colorectal cancer subtypes. (A) Colorectal cancer (n = 61) mutation profile and average methylation profile from normal colon whole genome bisulfite sequencing (WGBS) data, around transcription start sites (TSSs). Nucleotide-resolution mutation data (light beige), together with mutation data in 25 bp bins (dark beige) is shown. (B) Correlation between mutations per megabase (Mb) at CpG dinucleotides and fractions of CpGs methylated (using normal sigmoid colon tissue WGBS methylation data) across autosomes in Polymerase epsilon exonuclease domain mutation (POLE-mutant) colorectal cancers, those with microsatellite instability (MSI) or those that are microsatellite stable (MSS). Genome-wide data is binned for each colorectal cancer subtype (bins of 0.1 methylation), along with r2 and significance from Pearson's regression. The comparison of MSI and POLE-mutant slopes with MSS slopes was calculated by linear regression on binned data, with MSS as the reference factor.CC BY · PubMed Central
Figure 2. Association between mutation accumulation and methylation across changes in replication timing in colorectal cancers with differential mismatch repair. Correlation between mutations per megabase (Mb) at CpG dinucleotides and fractions of CpGs methylated (using normal sigmoid colon tissue WGBS methylation data) across autosomes in (A) microsatellite stable (MSS) colorectal cancers, and (B) colorectal cancers with microsatellite instability (MSI). Genome-wide data is binned for each colorectal cancer subtype (bins of 0.1 methylation), along with r2 and significance from Pearson's regression. The comparison of mid- and late-replicating slopes with early-replicating slopes was calculated by linear regression on binned data, with ‘early-replicating’ as the reference factor.
Figure 2. Association between mutation accumulation and methylation across changes in replication timing in colorectal cancers with differential mismatch repair. Correlation between mutations per megabase (Mb) at CpG dinucleotides and fractions of CpGs methylated (using normal sigmoid colon tissue WGBS methylation data) across autosomes in (A) microsatellite stable (MSS) colorectal cancers, and (B) colorectal cancers with microsatellite instability (MSI). Genome-wide data is binned for each colorectal cancer subtype (bins of 0.1 methylation), along with r2 and significance from Pearson's regression. The comparison of mid- and late-replicating slopes with early-replicating slopes was calculated by linear regression on binned data, with ‘early-replicating’ as the reference factor.CC BY · PubMed Central
Figure 3. Methylation-associated mutations in POLE-mutant colorectal cancers. (A) Correlation of total mutations per Polymerase epsilon exonuclease domain mutant (POLE-mutant) colorectal cancer sample, with the slope of line of best fit from the mutation–methylation association at Supplementary Figure S3. r2 and significance is by Pearson's correlation. (B) Percentage of candidate sites which harbour C>T mutations in a TCG context per sample for low (<25%) and high (>75%) methylated CpGs (using normal colon tissue methylation data) per POLE-mutant colorectal cancer sample. Mean and standard deviation are shown; significance is by unpaired t-test where **P < 0.01. (C) Strand-specificity of T[C>A]T (left) and T[C>T]G (right) mutations in the regions 5΄ and 3΄ to origins of replication (oriC) near TOP1 (top) and LMNB2 (bottom). Significance is by Fisher's exact test. (D) Excerpt from the UCSC genome browser, depicting strand specificity of T[C>A]T and T[C>T]G mutations 5΄ and 3΄ to the oriC near TOP1 (top) and LMNB2 (bottom).
Figure 3. Methylation-associated mutations in POLE-mutant colorectal cancers. (A) Correlation of total mutations per Polymerase epsilon exonuclease domain mutant (POLE-mutant) colorectal cancer sample, with the slope of line of best fit from the mutation–methylation association at Supplementary Figure S3. r2 and significance is by Pearson's correlation. (B) Percentage of candidate sites which harbour C>T mutations in a TCG context per sample for low (<25%) and high (>75%) methylated CpGs (using normal colon tissue methylation data) per POLE-mutant colorectal cancer sample. Mean and standard deviation are shown; significance is by unpaired t-test where **P < 0.01. (C) Strand-specificity of T[C>A]T (left) and T[C>T]G (right) mutations in the regions 5΄ and 3΄ to origins of replication (oriC) near TOP1 (top) and LMNB2 (bottom). Significance is by Fisher's exact test. (D) Excerpt from the UCSC genome browser, depicting strand specificity of T[C>A]T and T[C>T]G mutations 5΄ and 3΄ to the oriC near TOP1 (top) and LMNB2 (bottom).CC BY · PubMed Central
Figure 4. Mutation hotspots in cancer driver genes in POLE-mutant tumors. (A) Contingency table and significance from Fisher's exact test of Polymerase epsilon exonuclease domain mutant (POLE-mutant) and microsatellite stable (MSS) colorectal cancer samples which are wild-type or mutant at tumor protein p53 (TP53) R213 and adenomatous polyposis coli (APC) R1114 codons. (B) Methylation status in normal colon tissue for each CpG site within coding exons of TP53 and APC, together with significance by one-sample t-test against methylation at R213 and R1114 codons respectively. Mean and standard deviation are shown. ** denotes P < 0.01.
Figure 4. Mutation hotspots in cancer driver genes in POLE-mutant tumors. (A) Contingency table and significance from Fisher's exact test of Polymerase epsilon exonuclease domain mutant (POLE-mutant) and microsatellite stable (MSS) colorectal cancer samples which are wild-type or mutant at tumor protein p53 (TP53) R213 and adenomatous polyposis coli (APC) R1114 codons. (B) Methylation status in normal colon tissue for each CpG site within coding exons of TP53 and APC, together with significance by one-sample t-test against methylation at R213 and R1114 codons respectively. Mean and standard deviation are shown. ** denotes P < 0.01.CC BY · PubMed Central
Figure 5. Actual and predicted mutation rates, according to methylation and replication timing for colorectal cancer subtypes. Graphs depict actual and predicted (by regression model; see Materials and Methods) mutation probability and log odds of mutation probability by methylation or replication timing, for (A) microsatellite stable (MSS) colorectal cancer, (B) colorectal cancers with microsatellite instability (MSI) and (C) colorectal cancers with Polymerase epsilon exonuclease domain mutation (POLE-mutant). Graphs from left to right are: mutation probability by fraction of CpGs methylated (actual and predicted), log odds of mutation probability by fraction of CpGs methylated (actual and predicted), log odds of mutation probability by fraction of CpGs methylated (predicted, using overall average replication timing in all bins), log odds of mutation probability by replication timing (actual and predicted) and log odds of mutation probability by replication timing (predicted, using overall average methylation in all bins). Binned data is shown (bins of 0.1 for methylation or 10 for replication timing). See Table 1 for regression output, predicted vertex and area under curve values.
Figure 5. Actual and predicted mutation rates, according to methylation and replication timing for colorectal cancer subtypes. Graphs depict actual and predicted (by regression model; see Materials and Methods) mutation probability and log odds of mutation probability by methylation or replication timing, for (A) microsatellite stable (MSS) colorectal cancer, (B) colorectal cancers with microsatellite instability (MSI) and (C) colorectal cancers with Polymerase epsilon exonuclease domain mutation (POLE-mutant). Graphs from left to right are: mutation probability by fraction of CpGs methylated (actual and predicted), log odds of mutation probability by fraction of CpGs methylated (actual and predicted), log odds of mutation probability by fraction of CpGs methylated (predicted, using overall average replication timing in all bins), log odds of mutation probability by replication timing (actual and predicted) and log odds of mutation probability by replication timing (predicted, using overall average methylation in all bins). Binned data is shown (bins of 0.1 for methylation or 10 for replication timing). See Table 1 for regression output, predicted vertex and area under curve values.CC BY · PubMed Central
Figure 6. Actual and predicted mutation probability and regression function vertex according to methylation and replication timing for squamous cell carcinoma (SCC) subtypes. Graph depicting actual and predicted (by regression model; see Materials and Methods) mutation probability by fraction of CpGs methylated (actual and predicted) for (A) wild-type Xeroderma pigmentosum complementation group C (XPCwild-type) and (B) XPC mutant (XPC−/−) SCC. Binned data is shown (bins of 0.1 for methylation), with the function's vertex indicated by a dotted line. See Table 1 for regression output, predicted vertex and area under curve values. (C) Vertex predicted by regression model on individual XPCwild-type and XPC−/− SCC, with significance by unpaired t-test. Mean and standard deviation are shown. **** denotes P < 0.0001.
Figure 6. Actual and predicted mutation probability and regression function vertex according to methylation and replication timing for squamous cell carcinoma (SCC) subtypes. Graph depicting actual and predicted (by regression model; see Materials and Methods) mutation probability by fraction of CpGs methylated (actual and predicted) for (A) wild-type Xeroderma pigmentosum complementation group C (XPCwild-type) and (B) XPC mutant (XPC−/−) SCC. Binned data is shown (bins of 0.1 for methylation), with the function's vertex indicated by a dotted line. See Table 1 for regression output, predicted vertex and area under curve values. (C) Vertex predicted by regression model on individual XPCwild-type and XPC−/− SCC, with significance by unpaired t-test. Mean and standard deviation are shown. **** denotes P < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. 1983, Advances in Cancer Research, 1

Cited by

See all 94

Metadata

Authors
Poulos, R. C., Olivier, J., & Wong, J. W. H.
Affiliations
UNSW Sydney (AU)
Corresponding author
Wong, Jason W.H.
Venue
Nucleic Acids Research
Published
2017-05-22
Volume
45
Issue
13
Pages
7786-7795
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2620040559
Cited by
93
References
62
Citations by year
2026: 2 · 2025: 5 · 2024: 10 · 2023: 12 · 2022: 13 · 2021: 18 · 2020: 8 · 2019: 9 · 2018: 13 · 2017: 3
FWCI
3.03
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
Funders
  • Cancer Australia (APP1057921)
  • Cancer Institute NSW (13/DATA/1-02)
  • Medical Research Council
  • National Health and Medical Research Council (1119932)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
5-methylcytosine, DNA methylation, microsatellite instability, DNA mismatch repair, mutator phenotype, colorectal cancer, APC, TP53, DNA replication timing, DNA repair, tissue-specific methylation, mutational hotspots
MeSH terms
Poly-ADP-Ribose Binding Proteins, DNA Polymerase II, DNA Repair, DNA Replication, Humans, Mutation, Neoplasms, Colorectal Neoplasms, Genome, Human, Genes, p53, Genes, APC, CpG Islands, DNA Methylation, 5-Methylcytosine, Genes, Neoplasm, Microsatellite Instability, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes. https://app.cochat.ai/papers/10.1093/nar/gkx463
The paper
Poulos, R. C., Olivier, J., & Wong, J. W. H. (2017). The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes. Nucleic Acids Research. https://doi.org/10.1093/nar/gkx463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.